Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies.
OKMore info
THE BIOFARMA RESEARCH GROUP. UNIVERSITY OF SANTIAGO DE COMPOSTELA
We have a proven track record in applied research to early drug discovery in collaboration with both academia and biotechnological and pharmaceutical industries. We have been involved in early drug discovery programs of 15 new chemical entities (NCE) that entered in clinical trials. We have pioneered some the open innovation models that have been implemented in the pharmaceutical sector recently, which allowed a significant increase of the public-private collaboration initiatives.
It has an active participation in the development of networks and new models of open innovation in early drug discovery: It is coordinator of the Drug Discovery Galician Network (2007-onwards), the Spanish Drug Discovery Network of Excellence (REDEFAR) and the ES-OPENSCREEN Network connected to the ERIC EU- OPENSCREEN.
The group is the coordinator from the public side of the Joint Research Unit USC/Esteve: intensive collaboration with industry with more than 10 years of experience in the development of innovation in early drug discovery.
BioFarma carried out "INNOPHARMA", a Galician initiative in drug discovery that unites the capacities of the University of Santiago de Compostela Genomics and Drugs Screening Platforms, led respectively by Dr Ángel Carracedo and Dr Mabel Loza. It was financed by the EU Technology Fund, via the Spanish Ministry of Economy and Competitiveness. As a result of INNOPHARMA the Kærtor Foundation was created, as a non-for-profit foundation for promoting reciprocal transference in open innovation in drug discovery.
The major value of our group is the team. This team has a wide experience in the different aspects of assay development, assay miniaturization, design and execution of screening cascades, safety in vitro panels, ADME, etc. It is an international multidisciplinary effort with experts in constant adaptation to new technologies, which affords a great robustness in the translatability of results to clinical phases.
The members of the group have participated in the publication of more than 10 books and book chapters, more than 200 articles in indexed journals in the Journal Citation Report. The supervision of 23 PhD theses qualified with the highest mark have carried out, as well as more than 100 postgraduate research works.
The group regularly participates in national and international congresses in Pharmacology, Medicinal Chemistry and Drug Discovery, which more than 200 contributions.
Regarding to the equipment available, the group has modern and well-equipped laboratories for pharmacological screening of molecules, including: A cell culture facility; a Biosafety Level 2 laboratory; a molecular biology lab; an automated imaging unit (high-content screening); an assay development lab; an automated HTS unit with equipment and technologies to address the demand for throughput, storage capacity, and operational flexibility required for drug discovery projects; a chemical library which includes over 60000 compounds strategically assembled to be broadly diverse across "drug-like" structural space and functionality; a Chemical/Sample Temperature-Controlled Storage unit.
These infrastructures have allowed us to join the network of High Capacity Screening Centers for ERIC EU-OPENSCREEN (European Infrastructure of Open Screening Platforms for Chemical Biology). We have been collaborating with pharmaceutical and biotechnological companies in more than 50 projects/collaborations, as well as in more than 120 projects and contracts funded by either private or public bodies.
BioFarma Group | CIMUS Building, Avenida Barcelona S/N, 15782 Santiago de Compostela, A Coruña | Tel: 881 815 459 | Email: biofarma.group@usc.es